newsroom
Explore stories & events
Genetesis in the News

- 2020$10 Million Series B
- 2019FDA 510(K) Clearance
- 2018$7.5 Million Series A
- 20171st CardioFlux Installation
- 2016$1.5 Million Seed
- 2015Clinical Pilot (Mayo)
- 2014Prototyping
- 2013Founded
2020
$10 Million Series B
2019
FDA 510(K) Clearance
2018
$7.5 Million Series A
2017
1st CardioFlux Installation
2016
$1.5 Million Seed
2015
Clinical Pilot (Mayo)
2014
Prototyping
2013
Founded
2020
-
FDA awards Genetesis Breakthrough Device Designation for CardioFlux
-
Genetesis Added Significant Strategic Investor- TDK Ventures
-
Genetesis Brings Sajid Malhotra & Other Investors to Company
-
COVID-19 Further Overwhelms Chest Pain Triage Inefficiencies
-
8 Cincinnati Biotech Companies with Big Steps to Watch in 2020
-
MedAxiom Announces Industry Partnership with Genetesis, Inc.
-
Genetesis Pilot Study: 90 Second Scan Shows Promise in Evaluating Chest Pain Patients
-
WVU Heart and Vascular Institute Innovations Aim to Deal with Heart Disease, Imaging
-
‘Shark Tank’ Billionaire Mark Cuban Adds to Investment in Cincinnati Firm
-
Genetesis Lands Strategic Investment to Close Series B